Breast cancer |
BHLH40-AS1/IL-6/STAT3 |
Induction |
Promoting progression and proliferation |
[60] |
IL-6/STAT3 |
Induction |
Radiation induces STAT3-mediated inflammation and radio resistance |
[61] |
MiR-454/VGLL4/STAT3 |
Induction |
MiR-454 induces the STAT3 signaling pathway via VGLL4 downregulation, leading to cancer malignancy |
[62] |
PAK1/STAT3 |
Induction |
Stimulation of the nuclear translocation of STAT3 and enhancing breast cancer stem cell proliferation |
[63] |
SIRT4/IL-6/STAT3 |
Inhibition |
Sensitizing cancer cells to tamoxifen chemotherapy |
[64] |
Prostate cancer |
IL-8/STAT3/MALAT1 |
Induction |
STAT3 upregulates the expression of MALAT1, leading to progression and proliferation |
[65] |
MiR-17/JAK/STAT3 |
Inhibition |
MiR-17 reduces the expression of pro-survival factors, such as Bcl-2, and induces apoptosis via STAT3 downregulation |
[66] |
Bladder cancer |
MiR-4500/STAT3/CCR7 |
Inhibition |
Suppressing migration and proliferation |
[67] |
CD44/Akt/ERK/STAT3 |
Induction |
Inhibition of apoptosis and cell cycle arrest |
[68] |
Lung cancer |
B7-H4/PD-1/STAT3 |
Induction |
Promoting proliferation and invasion via immune evasion |
[69] |
KCP10043F/STAT3 |
Inhibition |
Induction of apoptotic cell death |
[70] |
BIS/STAT3 |
Induction |
Reducing sensitivity of cancer cells to digoxin-mediated migration and growth inhibition |
[71] |
Glioblastoma |
Annexin-A2/STAT3/oncostatin M receptor |
Induction |
Promoting the proliferation and invasion of cancer cells |
[72] |
Hsa-miR-181d/STAT3 |
Inhibition |
Garcinol upregulates the expression of hsa-miR-181d to inhibit STAT3 and the malignancy of cancer cells |
[73] |
TROP2/JAK2/STAT3 |
Induction |
Promoting proliferation and migration |
[74] |
Bradykinin B1 receptor/STAT3/IL-8 |
Induction |
Enhancing malignant behavior |
[75] |